Profile: Biomarin Pharmaceutical Inc. develops and distributes biopharmaceuticals for serious diseases & medical conditions. We offer Naglazyme® which is an enzyme replacement therapy for the treatment of mucopolysaccharidosis VI (MPS VI), an inherited life-threatening lysosomal storage disorder caused by the deficiency of the lysosomal enzyme N-acetylgalactosamine 4-sulfatase. Aldurazyme® (laronidase) is an enzyme replacement therapy for the treatment of mucopolysaccharidosis I (MPS I), an inherited, often life-threatening lysosomal disorder caused by the deficiency of alpha-L-iduronidase, a lysosomal enzyme.
FDA Registration Number: 3010085632
US Agent: Linda Wilbur
Phone: +1-(415)-506-6154 E-Mail:
1 Products/Services (Click for related suppliers)
|
• Bronchial Treatments |